CATALYST COMPOSITION FOR BIARYL SYNTHESIS BY DECARBOXYLATIVE CROSS-COUPLING

Abstract

The present invention relates to a catalyst composition for synthesis of heteroaromatic biaryls by a light-assisted decarboxylative carbon-carbon cross-coupling reaction, wherein the composition comprises (i) a palladium compound which is selected from a palladium salt or a palladium complex or a mixture thereof, (ii) at least one of the following compounds: a compound of Formula (I)

##STR00001## a compound of Formula (II)

##STR00002## an iridium complex comprising ligands L.sup.1, L.sup.2 and L.sup.3, wherein the ligands L.sup.1, L.sup.2 and L.sup.3 are selected, independently from each other, from a phenylpyridine and a bipyridine.

Claims

1. A composition comprising (i) a palladium compound which is selected from a palladium salt or a palladium complex or a mixture thereof; and (ii) at least one of the following compounds: a compound of Formula (I) ##STR00038## wherein R.sup.1 to R.sup.10 are selected independently from each other from hydrogen, and C.sub.1-4alkyl; or at least two of the residues R.sup.1 to R.sup.10 which are adjacent to each other form together with the carbon atoms to which they are attached a six-membered aromatic ring and, if present, the remaining residues are selected independently from each other from hydrogen and C.sub.1-4alkyl; a compound of Formula (II) ##STR00039## wherein R.sup.1 to R.sup.8 are selected independently from each other from hydrogen, C.sub.1-4alkyl and cyano; or at least two of the residues R.sup.1 to R.sup.8 which are adjacent to each other form together with the carbon atoms to which they are attached a six-membered aromatic ring and, if present, the remaining residues are selected independently from each other from hydrogen, C.sub.1-4alkyl and cyano; an iridium complex comprising ligands L.sup.1, L.sup.2 and L.sup.3, wherein the ligands L.sup.1, L.sup.2 and L.sup.3 are selected independently from each other from a phenylpyridine and a bipyridine.

2. The composition according to claim 1, comprising both the compound of Formula (I) and the compound of Formula (II).

3. The composition according to claim 1, wherein, in the iridium complex, the ligand L.sup.1 is a bipyridine and each of the ligands L.sup.2 and L.sup.3 is a phenylpyridine.

4. The composition according to claim 3, wherein the iridium complex has the following Formula (III-4): ##STR00040##

5. The composition according to claim 1, wherein the palladium salt is a palladium acetate, a palladium acetylacetonate, a palladium halide, or any mixture thereof.

6. The composition according to claim 1, wherein the palladium complex comprises one or more ligands which are selected from a phosphine, a 1,4-dien-3-one, a N-heterocyclic carbene, an aryl, a nitrile, a polyene, an amine, and any combination thereof.

7. The composition according to claim 1, further comprising a component (iii) which is selected from a phosphine, a bipyridine, a cyclic diamine and any mixture thereof.

8. The composition according to claim 7, wherein the phosphine of component (iii) is selected from one or more of the following compounds: a phosphine of Formula (IV):
P(R.sup.1)(R.sup.2)(R.sup.3)(IV) wherein R.sup.1 and R.sup.2 are selected independently from each other from C.sub.1-6 alkyl and C.sub.5-7-cycloalkyl, R.sup.3 is biphenyl which is optionally substituted with one or more R.sup.4, R.sup.4, if present, is C.sub.1-6 alkyl, C.sub.1-6 alkoxy, phenyl or pyridyl; a phosphine of Formula (V):
P(R.sup.1)(R.sup.2)(R.sup.3)(V) wherein each of R.sup.1 to R.sup.3 is C.sub.1-6alkyl, or each of R.sup.1 to R.sup.3 is C.sub.5-7cycloalkyl, or R.sup.1 to R.sup.3 are selected independently from each other from aryl and heteroaryl, each of which is optionally substituted with one or more C.sub.1-4 haloalkyl, C.sub.1-4 alkyl or C.sub.1-4 alkoxy; a ferrocenyl diphosphine; a xanthenyl diphosphine; a diphosphine of Formula (VIII):
(R.sup.1)(R.sup.2)P(CH.sub.2).sub.nP(R.sup.3)(R.sup.4)(VIII) wherein n is 1 to 6, R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are selected independently from each other from phenyl and cyclohexyl, each of which is optionally substituted with one or more C.sub.1-4alkyl; a 2,3-dihydrobenzo[d][1,3]oxaphosphole; and a diadamantyl-C.sub.1-6alkyl-phosphine.

9. The composition according to claim 1, wherein the palladium complex of component (i) has one of the following Formulas (XI), (XIV), (XVI) or (XVII): ##STR00041## wherein in Formula (XI) L.sup.1 is a bivalent linker; R.sup.1 and R.sup.2 are selected independently from each other from hydrogen and C.sub.1-4alkyl; or R.sup.1 and R.sup.2 together with the nitrogen atom to which they are attached form a five- or six-membered ring; R.sup.3, R.sup.4, R.sup.5, and R.sup.6 are selected independently from each other from hydrogen and C.sub.1-4alkyl; or at least two of the residues R.sup.3 to R.sup.6 which are adjacent to each other form together with the carbon atoms to which they are attached a five- or six-membered aromatic ring and, if present, the remaining residues are selected independently from each other from hydrogen and C.sub.1-4alkyl; and Lg.sup.1 and Lg.sup.2 are independently from each other a non-ionic ligand; ##STR00042## wherein in Formula (XIV) L.sup.1 is a bivalent linker; R.sup.1 and R.sup.2 are selected independently from each other from hydrogen and C.sub.1-4 alkyl; or R.sup.1 and R.sup.2 together with the nitrogen atom to which they are attached form a five- or six-membered ring; R.sup.3, R.sup.4, R.sup.5, and R.sup.6 are selected independently from each other from hydrogen and C.sub.1-4 alkyl; or at least two of the residues R.sup.3 to R.sup.6 which are adjacent to each other form together with the carbon atoms to which they are attached a five- or six-membered aromatic ring and, if present, the remaining residues are selected independently from each other from hydrogen and C.sub.1-4alkyl; Lg.sup.1 is a non-ionic ligand; and Lg.sup.2 is an anionic ligand;
Pd(L).sub.3-4(XVI) wherein in Formula (XVI) the ligands L are independently from each other a triaryl phosphine, wherein each aryl group is optionally substituted with one or more R.sup.1; and R.sup.1, if present, is C.sub.1-4haloalkyl, C.sub.1-4alkyl or C.sub.1-4alkoxy; and ##STR00043## wherein in Formula (XVII) Lg-Lg is a chelating ferrocenyl diphosphine ligand; and X is a halide.

10. The composition according to claim 1, wherein the composition comprises a mixture of the palladium compound and the one or more compounds of component (ii) and optionally a component (iii) selected from a phosphine, a bipyridine, a cyclic diamine and any mixture thereof; or the composition is a kit-of-parts which provides the palladium compound and the one or more compounds of component (ii) and optionally the component (iii) in separate containers.

11. A process which comprises mixing a first reactant, a second reactant and a composition according to claim 1, thereby providing a reaction medium, wherein the first reactant is a compound which comprises a heterocyclic aromatic ring AR1 to which a carboxylic acid group, a carboxylate group or a carboxylic acid ester group is attached, and the second reactant is a compound which comprises an aromatic ring AR2 to which a halogen atom, a pseudohalogen group or a sulfonate group is attached, irradiating the reaction medium by an external source of artificial, thereby coupling the heterocyclic aromatic ring AR1 of the first reactant to the aromatic ring AR2 of the second reactant by a decarboxylative carbon-carbon cross-coupling reaction.

12. A process which comprises mixing a reactant and the composition according to claim 1, thereby providing a reaction medium, wherein the reactant is a compound which comprises a heterocyclic aromatic ring AR1 to which a carboxylic acid group, a carboxylate group or a carboxylic acid ester group is attached, and an aromatic ring AR2 to which a halogen atom, a pseudohalogen group or a sulfonate group is attached, irradiating the reaction medium by an external source of artificial light, thereby coupling the heterocyclic aromatic ring AR1 and the aromatic ring AR2 of the reactant to each other by a decarboxylative carbon-carbon cross-coupling reaction.

13. The process according to claim 12, wherein the carboxylic acid ester group attached to the heterocyclic aromatic ring AR1 has the following formula (XVIII):
C(O)O-A(XVIII) wherein the residue A is derived from a N-hydroxy compound.

14. The process according claim 12, wherein the reactants and the composition are mixed with each other in a solvent which comprises a polar aprotic solvent.

15. The process according to claim 12, wherein the external light source is a lamp, a LED, a laser, or any combination of two or more of these external light sources.

16. (canceled)

17. The process according to claim 11, wherein the carboxylic acid ester group attached to the heterocyclic aromatic ring AR1 has the following formula (XVIII):
C(O)O-A(XVIII) wherein the residue A is derived from a N-hydroxy compound.

18. The process according to claim 11, wherein the reactants and the composition are mixed with each other in a solvent which comprises a polar aprotic solvent.

19. The process according to claim 11, wherein the external light source is a lamp, a LED, a laser, or any combination of two or more of these external light sources.

Description

DETAILED DESCRIPTION

[0055] As already outlined above, the catalyst composition of the present invention comprises a palladium compound (i.e. component (i)) and at least one of the compounds of component (ii).

[0056] If a heteroaryl carboxylic acid or a carboxylate or an ester thereof is reacted with a (hetero)aryl halide (or a (hetero)aryl pseudohalide or a (hetero)aryl sulfonate) in a reaction medium [0057] to which the composition of the present invention has been added and [0058] which is irradiated by an external light source,

[0059] a heteroaromatic biaryl compound can be formed by a decarboxylative carbon-carbon cross-coupling reaction even at rather moderate reaction temperature (e.g. 70 C. or even less).

[0060] However, no heteroaromatic biaryl compound is formed from these reactants at moderate reaction temperature if [0061] the reaction medium comprises the palladium compound and is irradiated by an external light source but no compound of component (ii) is present, or [0062] the reaction medium comprises both the palladium compound and at least one compound of component (ii) but is not irradiated by an external light source.

[0063] If component (ii) of the composition comprises the compound of Formula (I), it is preferred that each of the residues R.sup.1 to R.sup.10 is hydrogen; or R.sub.2 to R.sup.9 are hydrogen and R.sup.1 and R.sup.10 (which are considered to represent adjacent residues) form together with the carbon atoms to which they are attached a six-membered carbocyclic aromatic ring.

[0064] Accordingly, a preferred compound of Formula (I) has the following Formula (I-1) or Formula (I-2):

##STR00005##

[0065] In a preferred embodiment, each of the residues R.sup.1 to R.sup.10 of the compound of Formula (I) is hydrogen

[0066] If component (ii) of the composition comprises the compound of Formula (II), it may have one of the Formulas (II-1) to (II-4):

##STR00006##

[0067] In a preferred embodiment, each of the residues R.sup.1 to R.sup.8 of Formula (II) is hydrogen (i.e. compound of Formula (II-1)).

[0068] It might be preferred that the composition comprises both the compound of Formula (I) (e.g. the compound of Formula (I-1)) and the compound of Formula (II) (e.g. the compound of Formula (II-1)).

[0069] As already mentioned above, if component (ii) of the composition comprises the iridium complex, the ligands L.sup.1, L.sup.2 and L.sup.3 of said iridium complex are selected independently from each other from a phenylpyridine (which might be substituted or unsubstituted) and a bipyridine (which might be substituted or unsubstituted). It is preferred that the ligand L.sup.1 is a bipyridine and each of the ligands L.sup.2 and L.sup.3 is a phenylpyridine.

[0070] According to an exemplary embodiment, the ligand L.sup.1 of the iridium complex is a bipyridine of Formula (III-1)

##STR00007## [0071] wherein [0072] R.sup.1 and R.sup.2 are selected independently from each other from hydrogen and C.sub.1-6alkyl; and [0073] the arrows indicate by which atoms the ligand L.sup.1 coordinates to the iridium atom of the iridium complex; [0074] the ligand L.sup.2 of the iridium complex is a phenylpyridine of Formula (III-2)

##STR00008## [0075] wherein [0076] R.sup.3 is selected from hydrogen, C.sub.1-4alkyl (preferably methyl) and fluoro-C.sub.1-4alkyl (preferably trifluoromethyl); [0077] R.sup.4 and R.sup.5 are selected independently from each other from hydrogen and fluoro (F), under the proviso that at least one of the residues R.sup.4 and R.sup.5 is fluoro; and [0078] the arrows indicate by which atoms the ligand L.sup.2 coordinates to the iridium atom of the iridium complex;

[0079] the ligand L.sup.3 of the iridium complex is a phenylpyridine of Formula (I-3)

##STR00009## [0080] wherein [0081] R.sup.8 is selected from hydrogen, C.sub.1-4alkyl (preferably methyl) and fluoro-C.sub.1-4alkyl (preferably trifluoromethyl); [0082] R.sup.6 and R.sup.7 are selected independently from each other from hydrogen and fluoro (F), under the proviso that at least one of the residues R.sup.6 and R.sup.7 is fluoro; and [0083] the arrows indicate by which atoms the ligand L.sup.3 coordinates to the iridium atom of the iridium complex.

[0084] In a preferred embodiment, the iridium complex has the following formula (III-4):

##STR00010##

[0085] The iridium complex of component (ii) may optionally comprise further ligands. However, it is preferred that no ligands other than L.sup.1, L.sup.2 and L.sup.3 are present in the iridium complex.

[0086] If the iridium complex is a cationic iridium complex (i.e. a positively charged iridium complex), it might be associated with one or more charge-compensating anions, e.g. one or more weakly coordinating anions such as [BF.sub.4].sup., [ClO.sub.4], [SbF.sub.6].sup. and [PF.sub.6].sup.. However, other anions might be present as well.

[0087] As outlined above, the composition of the present invention comprises as component (i) a palladium compound which is a palladium salt or a palladium complex or a mixture thereof.

[0088] If the palladium compound of component (i) is a palladium salt, it might be a palladium acetate (e.g. Pd(OAc).sub.2), a palladium acetylacetonate (e.g. Pd(acac).sub.2) or a palladium halide (such as palladium chloride, palladium bromide or palladium iodide), or any mixture thereof.

[0089] If the palladium compound of component (i) is a palladium complex, it might comprise one or more ligands which are selected from a phosphine, a 1,4-dien-3-one (e.g. dibenzylideneacetone), a N-heterocyclic carbene, an aryl, a nitrile (e.g. acetonitrile, propionitrile or benzonitrile), a polyene (e.g. a polyene having 2 to 4 carbon-carbon double bonds, in particular a cyclic polyene such as cyclooctadiene or cyclooctatetraene), an amine, or any combination thereof. In addition to one or more of these ligands, the palladium complex may comprise other ligands as well, such as a halide, a pseudohalide (e.g. CN.sup. or OCN.sup.), an acetylacetonate or a carboxylate (e.g. acetate).

[0090] If the palladium complex of component (i) does not comprise any phosphine ligand, it will be referred to as a phosphine-free palladium complex. The phosphine-free palladium complex may comprise one or more of the non-phosphine ligands mentioned above, i.e. a 1,4-dien-3-one (e.g. dibenzylideneacetone), a N-heterocyclic carbene, an aryl, a nitrile (e.g. acetonitrile, propionitrile or benzonitrile), a polyene (e.g. a polyene having 2 to 4 carbon-carbon double bonds, in particular a cyclic polyene such as cyclooctadiene (COD) or cyclooctatetraene), an amine, or any combination thereof. In addition to one or more of these ligands, the phosphine-free palladium complex may comprise other ligands as well, such as a halide, a pseudohalide (e.g. CN.sup. or OCN.sup.), an acetylacetonate or a carboxylate (e.g. acetate). An exemplary phosphine-free palladium complex is a palladium complex comprising one or more ligands of dibenzylideneacetone (e.g. bis(dibenzylideneacetone)palladium or tris(dibenzylideneacetone)dipalladium) or a palladium complex comprising one or more ligands of a cyclic polyene such as cyclooctadiene (COD) or cyclooctatetraene (e.g. Pd(COD)Cl.sub.2).

[0091] Optionally, the composition of the present invention may comprise a component (iii) which is selected from a phosphine, a bipyridine and a cyclic diamine or a mixture of at least two of these compounds. Preferably, the composition comprises the compound of component (iii) if the palladium compound of component (i) is a palladium salt or a phosphine-free palladium complex (e.g. a phosphine-free palladium complex comprising one or more ligands selected from dibenzylideneacetone and a cyclic polyene such as cyclooctadiene (COD) or cyclooctatetraene). If the compound of component (iii) is added to the reaction medium together with the palladium compound of component (i), it may subsequently coordinate as a ligand to the palladium atom of the palladium compound.

[0092] If the palladium compound of component (i) is a palladium complex which comprises a phosphine as a ligand and the composition further comprises a phosphine compound as component (iii), it is preferred that the phosphine ligand and the phosphine compound of component (iii) are different from each other.

[0093] The palladium compound (in particular the palladium salt or the phosphine-free palladium complex) of component (i) and the compound of component (iii) might be kept in separate containers and brought into contact when performing the decarboxylative cross-coupling reaction, thereby forming in situ a palladium complex.

[0094] According to an exemplary embodiment, the phosphine of component (iii) is of Formula (IV):

P(R.sup.1)(R.sup.2)(R.sup.3)(IV)

[0095] wherein [0096] R.sup.1 and R.sup.2 are selected independently from each other from C.sub.1-6 alkyl and C.sub.5-7-cycloalkyl (e.g. cyclohexyl); [0097] R.sup.3 is biphenyl which is optionally substituted with one or more R.sup.4; [0098] R.sup.4, if present, is C.sub.1-6 alkyl, C.sub.1-6 alkoxy, phenyl or pyridyl (more preferably C.sub.1-6 alkyl or C.sub.1-6 alkoxy).

[0099] The phosphine of Formula (IV) may have one of the following Formulas (IV-1) to (IV-6):

##STR00011##

[0100] According to another exemplary embodiment, the phosphine of component (iii) is of Formula (V):

P(R.sup.1)(R.sup.2)(R.sup.3)(V)

[0101] wherein [0102] each of R.sup.1 to R.sup.3 is C.sub.1-6alkyl; or [0103] each of R.sup.1 to R.sup.3 is C.sub.5-7cycloalkyl (e.g. cyclohexyl); or [0104] R.sup.1 to R.sup.3 are selected independently from each other from aryl (e.g. phenyl) and heteroaryl (e.g. pyridyl) each of which is optionally substituted with one or more C.sub.1-4 haloalkyl (e.g. CF.sub.3), C.sub.1-4 alkyl (e.g. methyl) or C.sub.1-4 alkoxy (e.g. methoxy).

[0105] The phosphine of Formula (V) may have one of the following Formulas (V-1) to (V-6):

##STR00012##

[0106] According to another exemplary embodiment, the phosphine of component (iii) is a ferrocenyl diphosphine or a xanthenyl diphosphine.

[0107] The ferrocenyl diphosphine may have one of the following Formulas (VI-1) to (VI-2):

##STR00013##

[0108] The xanthenyl diphosphine may have the following Formula (VII-1):

##STR00014##

[0109] According to another exemplary embodiment, the phosphine of component (iii) is a diphosphine of Formula (VIII):

(R.sup.1)(R.sup.2)P(CH.sub.2).sub.nP(R.sup.3)(R.sup.4)(VIII)

[0110] wherein [0111] n is 1 to 6, more preferably 2 to 4; [0112] R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are selected independently from each other from phenyl and cyclohexyl, each of which is optionally substituted with one or more C.sub.1-4alkyl.

[0113] The phosphine of Formula (VIII) may have one of the following Formulas (VIII-1) to (VIII-3):

##STR00015##

[0114] According to another exemplary embodiment, the phosphine of component (iii) is a 2,3-dihydrobenzo[d][1,3]oxaphosphole.

[0115] The 2,3-dihydrobenzo[d][1,3]oxaphosphole may have the following Formula (IX):

##STR00016##

[0116] wherein [0117] R.sup.1 to R.sup.3 are selected independently from each other from hydrogen and C.sub.1-4alkyl.

[0118] According to an exemplary embodiment, the 2,3-dihydrobenzo[d][1,3]oxaphosphole may have the following Formula (IX-1):

##STR00017##

[0119] According to another exemplary embodiment, the phosphine of component (iii) is a diadamantyl-C.sub.1-6alkyl-phosphine.

[0120] The diadamantyl-C.sub.1-6alkyl-phosphine may have the following Formula (X-1):

##STR00018##

[0121] The cyclic diamine of component (iii) is preferably a bicyclic diamine such as 1,4-diazabicyclo[2.2.2]octane (DABCO).

[0122] According to an exemplary embodiment of the present invention, the composition comprises (i) a palladium salt (such as a palladium acetate, a palladium acetylacetonate or a palladium halide) or a phosphine-free palladium complex (e.g. a phosphine-free palladium complex comprising one or more ligands which are selected from a 1,4-dien-3-one (e.g. dibenzylideneacetone), a N-heterocyclic carbene, an aryl, a nitrile (e.g. acetonitrile, propionitrile or benzonitrile), a polyene (e.g. a polyene having 2 to 4 carbon-carbon double bonds, in particular a cyclic polyene such as cyclooctadiene (COD) or cyclooctatetraene) and an amine, and optionally comprising one or more additional ligands which are selected from a halide, a pseudohalide, an acetylacetonate and a carboxylate (e.g. acetate)); (ii) a compound of Formula (I) and/or Formula (II); and (iii) a phosphine of Formula (IV) as outlined above (such as the phosphines of Formulas (IV-1) to (IV-6)). Preferably, the composition comprises both the compound of Formula (I) and the compound of Formula (II), e.g. the compounds of Formula (I-1) and (11-1). A preferred phosphine-free palladium complex comprises one or more ligands selected from dibenzylideneacetone and a cyclic polyene such as cyclooctadiene (COD) or cyclooctatetraene. Preferably, the phosphine of component (iii) is of Formula (IV-6) indicated above.

[0123] According to another exemplary embodiment of the present invention, the composition comprises (i) a palladium salt (such as a palladium acetate, a palladium acetylacetonate or a palladium halide) or a phosphine-free palladium complex (e.g. a phosphine-free palladium complex comprising one or more ligands which are selected from a 1,4-dien-3-one (e.g. dibenzylideneacetone), a N-heterocyclic carbene, an aryl, a nitrile (e.g. acetonitrile, propionitrile or benzonitrile), a polyene (e.g. a polyene having 2 to 4 carbon-carbon double bonds, in particular a cyclic polyene such as cyclooctadiene (COD) or cyclooctatetraene) and an amine, and optionally comprising one or more additional ligands which are selected from a halide, a pseudohalide, an acetylacetonate and a carboxylate (e.g. acetate)); (ii) an iridium complex comprising ligands L.sup.1, L.sup.2 and L.sup.3, wherein the ligand L.sup.1 is a bipyridine (e.g. of Formula (III-1)) and the ligands L.sup.2 and L.sup.3 are phenylpyridines (e.g. of Formulas (III-2) and (III-3)); and (iii) a phosphine of Formula (IV) as outlined above (such as the phosphines of Formulas (IV-1) to (IV-6)). Preferably, the iridium complex has the Formula (III-4) outlined above. A preferred phosphine-free palladium complex comprises one or more ligands selected from dibenzylideneacetone and a cyclic polyene such as cyclooctadiene (COD) or cyclooctatetraene. Preferably, the phosphine of component (iii) has the Formula (IV-4) outlined above.

[0124] As already indicated above, if the palladium compound of component (i) is a palladium complex, it may comprise one or more ligands which are selected from a phosphine, a 1,4-dien-3-one (e.g. dibenzylideneacetone), an N-heterocyclic carbene, an aryl, a nitrile (e.g. acetonitrile, propionitrile or benzonitrile), a polyene (e.g. a polyene having 2 to 4 carbon-carbon double bonds, in particular a cyclic polyene such as cyclooctadiene or cyclooctatetraene), an amine, or any combination thereof. In addition to these ligands, the palladium complex may comprise other ligands as well, e.g. a halide (e.g. Cl.sup., Br.sup.), a pseudohalide (e.g. CN.sup. or OCN.sup.), an acetylacetonate or a carboxylate (e.g. acetate).

[0125] In an exemplary embodiment of the present invention, the palladium complex of component (i) is of Formula (XI)

##STR00019##

[0126] wherein [0127] L.sup.1 is a bivalent linker; [0128] R.sup.1 and R.sup.2 are selected independently from each other from hydrogen and C.sub.1-4alkyl; or R.sup.1 and R.sup.2 together with the nitrogen atom to which they are attached form a five- or six-membered ring (which might be an aromatic or non-aromatic ring); [0129] R.sup.3, R.sup.4, R.sup.5, and R.sup.6 are selected independently from each other from hydrogen and C.sub.1-4alkyl; or at least two of the residues R.sup.3 to R.sup.6 which are adjacent to each other form together with the carbon atoms to which they are attached a five- or six-membered aromatic ring and, if present, the remaining residues (i.e. those of the residues R.sup.3 to R.sup.6 which do not form a ring) are selected independently from each other from hydrogen and C.sub.1-4alkyl; [0130] Lg.sup.1 and Lg.sup.2 are independently from each other a non-ionic ligand.

[0131] The compound of Formula (XI) might be associated with one or more charge-compensating anions, e.g. one or more weakly coordinating anions such as [BF.sub.4].sup., [ClO.sub.4].sup., [SbF.sub.6].sup. and [PF.sub.6].sup.. However, other anions might be present as well.

[0132] Preferably, ligand Lg.sup.2 is an N-heterocyclic carbene; and/or ligand Lg.sup.1 is a pyridine, a pyrrole, an imidazole, a pyrazole or a pyrimidine, each of which is optionally substituted with one or more halogens.

[0133] According to an exemplary embodiment of Formula (XI), [0134] L.sup.1 is C.sub.1-3 alkylene (e.g. CH.sub.2; CH.sub.2CH.sub.2; CH.sub.2CH.sub.2CH.sub.2); [0135] Lg.sup.1 is a pyridine, a pyrrole, an imidazole, a pyrazole or a pyrimidine, each of which is optionally substituted with one or more halogens; [0136] Lg.sup.2 is an N-heterocyclic carbene;

[0137] The N-heterocyclic carbene ligand Lg.sup.2 can be of Formula (XII) or Formula (XIII):

##STR00020##

[0138] wherein in Formula (XII) [0139] R.sup.3 to R.sup.16 are selected independently from each other from hydrogen and C.sub.1-4alkyl; or at least two of the residues R.sup.3 to R.sup.16 which are adjacent to each other form together with the carbon atoms to which they are attached a 5- or 6-membered ring and, if present, the remaining residues (i.e. those of the residues R.sup.3 to R.sup.16 not forming a ring) are selected independently from each other from hydrogen and C.sub.1-4alkyl;

##STR00021##

[0140] wherein in Formula (XIII) [0141] R.sup.3 to R.sup.14 are selected independently from each other from hydrogen and C.sub.1-4 alkyl; or at least two of the residues R.sup.3 to R.sup.14 which are adjacent to each other form together with the carbon atoms to which they are attached a 5- or 6-membered ring and, if present, the remaining residues (i.e. those of the residues R.sup.3 to R.sup.14 not forming a ring) are selected independently from each other from hydrogen and C.sub.1-4alkyl.

[0142] An exemplary palladium complex of Formula (XI) has the following Formula (XI-1):

##STR00022##

[0143] According to an exemplary embodiment of the present invention, the composition comprises (i) a palladium complex of Formula (XI); and (ii) a compound of Formula (I) and/or Formula (II). Preferably, ligand Lg.sup.2 in Formula (XI) is a N-heterocyclic carbene (e.g. of Formula (XII) or (XIII)); and/or ligand Lg.sup.1 is a pyridine, a pyrrole, an imidazole, a pyrazole or a pyrimidine, each of which is optionally substituted with one or more halogens. Preferably, the composition comprises both the compound of Formula (I) and the compound of Formula (II), e.g. the compounds of Formula (I-1) and (II-1).

[0144] According to another exemplary embodiment of the present invention, the composition comprises (i) a palladium complex of Formula (XI); and (ii) an iridium complex comprising ligands L.sup.1, L.sup.2 and L.sup.3, wherein the ligand L.sup.1 is a bipyridine (e.g. of Formula (III-1)) and the ligands L.sup.2 and L.sup.3 are phenylpyridines (e.g. of Formulas (III-2) and (III-3)). Preferably, ligand Lg.sup.2 in Formula (XI) is a N-heterocyclic carbene (e.g. of Formula (XII) or (XIII)); and/or ligand Lg.sup.1 is a pyridine, a pyrrole, an imidazole, a pyrazole or a pyrimidine, each of which is optionally substituted with one or more halogens. Preferably, the iridium complex has the Formula (III-4) outlined above.

[0145] According to another exemplary embodiment, the palladium complex of component (i) can be of Formula (XIV)

##STR00023##

[0146] wherein [0147] L.sup.1 is a bivalent linker; [0148] R.sup.1 and R.sup.2 are selected independently from each other from hydrogen and C.sub.1-4 alkyl; or R.sup.1 and R.sup.2 together with the nitrogen atom to which they are attached form a five- or six-membered ring; [0149] R.sup.3, R.sup.4, R.sup.5, and R.sup.6 are selected independently from each other from hydrogen and C.sub.1-4 alkyl; or at least two of the residues R.sup.3 to R.sup.6 which are adjacent to each other form together with the carbon atoms to which they are attached a five- or six-membered aromatic ring and, if present, the remaining residues (i.e. those of the residues R.sup.3 to R.sup.6 which do not form a ring) are selected independently from each other from hydrogen and C.sub.1-4alkyl; [0150] Lg.sup.1 is a non-ionic ligand; [0151] Lg.sup.2 is an anionic ligand.

[0152] Preferably, the non-ionic ligand Lg.sup.1 in Formula (XIV) is a phosphine.

[0153] The anionic ligand Lg.sup.2 in Formula (XIV) might be an alkyl sulfonate (e.g. mesylate) or an aryl sulfonate (e.g. tosylate). However, other anionic ligands might be used as well.

[0154] In an exemplary embodiment of Formula (XIV), [0155] L.sup.1 is phenylene (e.g. 1,2-phenylene) or C.sub.1-3alkylene (e.g. CH.sub.2; CH.sub.2CH.sub.2; [0156] CH.sub.2CH.sub.2CH.sub.2); [0157] the non-ionic ligand Lg.sup.1 is a phosphine, [0158] the anionic ligand Lg.sup.2 is an alkyl sulfonate (e.g. mesylate) or an aryl sulfonate (e.g. tosylate).

[0159] The phosphine ligand Lg.sup.1 in Formula (XIV) can be phosphine of Formula (XV):

P(R.sup.1)(R.sup.2)(R.sup.3)(XV)

[0160] wherein [0161] R.sup.1 and R.sup.2 are selected independently from each other from C.sub.1-6alkyl, C.sub.5-7cycloalkyl (in particular cyclohexyl) and phenyl, wherein phenyl is optionally substituted with one or more C.sub.1-4 alkyl, [0162] R.sup.3 is biphenyl or binaphthyl, each of which is optionally substituted with one or more R.sup.4, [0163] R.sup.4, if present, is C.sub.1-6alkyl, NH.sub.2, N(H)(C.sub.1-6alkyl), N(C.sub.1-6alkyl).sub.2, P(Phenyl).sub.2, or OC.sub.1-6alkyl.

[0164] Exemplary palladium complexes of Formula (XIV) can have one of the following Formulas (XIV-1) to Formula (XIV-7):

##STR00024## ##STR00025##

[0165] According to another exemplary embodiment, the phosphine ligand Lg.sup.1 in Formula (XIV) is a ferrocenyl diphosphine.

[0166] Exemplary palladium complexes of Formula (XIV) containing a ferrocenyl diphosphine ligand are those of Formula (XIV-8) or Formula (XIV-9):

##STR00026##

[0167] According to another exemplary embodiment, the phosphine ligand Lg.sup.1 in Formula (XIV) is a trialkyl phosphine (e.g. P(C.sub.1-6 alkyl).sub.3). An exemplary palladium complex of Formula (XIV) containing an trialkyl phosphine ligand is the palladium complex of Formula (XIV-10):

##STR00027##

[0168] Other exemplary palladium complexes of Formula (XIV) containing a phosphine ligand Lg.sup.1 are those of Formula (XIV-11), (XIV-12), or (XIV-13):

##STR00028##

[0169] According to an exemplary embodiment of the present invention, the composition comprises (i) a palladium complex of Formula (XIV); and (ii) a compound of Formula (I) and/or Formula (II). Preferably, the non-ionic ligand Lg.sup.1 in Formula (XIV) is a phosphine (e.g. a phosphine of Formula (XV), a ferrocenyl phosphine or a phosphine in one of the Formulas (XIV-11) to (XIV-13)). Preferably, the composition comprises both the compound of Formula (I) and the compound of Formula (II), e.g. the compounds of Formulas (I-1) and (II-1).

[0170] According to another exemplary embodiment of the present invention, the composition comprises (i) a palladium complex of Formula (XIV); and (ii) an iridium complex comprising ligands L.sup.1, L.sup.2 and L.sup.3, wherein the ligand L.sup.1 is a bipyridine (e.g. of Formula (III-1)) and the ligands L.sup.2 and L.sup.3 are phenylpyridines (e.g. of Formulas (III-2) and (III-3)). Preferably, the non-ionic ligand Lg.sup.1 in Formula (XIV) is a phosphine (e.g. a phosphine of Formula (XV), a ferrocenyl phosphine or a phosphine in one of the Formulas (XIV-11) to (XIV-13)). Preferably, the iridium complex has the Formula (III-4) outlined above.

[0171] According to an exemplary embodiment, the palladium complex of component (i) can be of Formula (XVI):

Pd(L).sub.3-4(XVI)

[0172] wherein [0173] the ligands L are, independently from each other, a triaryl phosphine (preferably a triphenyl phosphine), wherein each aryl group (which preferably is a phenyl group) is optionally substituted with one or more R.sup.1, [0174] R.sup.1, if present, is C.sub.1-4haloalkyl (e.g. CF.sub.3), C.sub.1-4alkyl (e.g. methyl) or C.sub.1-4alkoxy (e.g. methoxy).

[0175] Exemplary palladium complexes of Formula (XVI) are those of Formula (XVI-1) or (XVI-2):

##STR00029##

[0176] According to an exemplary embodiment of the present invention, the composition comprises (i) a palladium complex of Formula (XVI); and (ii) a compound of Formula (I) and/or Formula (II), e.g. the compounds of Formulas (I-1) and (II-1).

[0177] According to another exemplary embodiment of the present invention, the composition comprises (i) a palladium complex of Formula (XVI); and (ii) an iridium complex comprising ligands L.sup.1, L.sup.2 and L.sup.3, wherein the ligand L.sup.1 is a bipyridine (e.g. of Formula (III-1)) and the ligands L.sup.2 and L.sup.3 are phenylpyridines (e.g. of Formulas (III-2) and (III-3)). Preferably, the iridium complex has the Formula (III-4) outlined above.

[0178] According to another exemplary embodiment, the palladium complex of component (i) can be of Formula (XVII):

##STR00030##

[0179] wherein [0180] Lg-Lg is a chelating ferrocenyl diphosphine ligand, [0181] X is a halide (e.g. Cl).

[0182] Exemplary palladium complexes of Formula (XVII) are those of Formula (XVII-1) or (XVII-2):

##STR00031##

[0183] According to an exemplary embodiment of the present invention, the composition comprises (i) a palladium complex of Formula (XVII); and (ii) a compound of Formula (I) and/or Formula (II), e.g. the compounds of Formulas (I-1) and (II-1).

[0184] According to another exemplary embodiment of the present invention, the composition comprises (i) a palladium complex of Formula (XVII); and (ii) an iridium complex comprising ligands L.sup.1, L.sup.2 and L.sup.3, wherein the ligand L.sup.1 is a bipyridine (e.g. of Formula (III-1)) and the ligands L.sup.2 and L.sup.3 are phenylpyridines (e.g. of Formulas (III-2) and (III-3)). Preferably, the iridium complex has the Formula (III-4) outlined above.

[0185] The composition may contain the palladium compound of component (i) and the compound of component (ii) in the form of a mixture. Optionally, a compound of component (iii) and/or other additional components might be present in the mixture. Alternatively, the mixture may consist of the palladium compound and the one or more compounds of component (ii).

[0186] It might be preferred that no compound comprising a transition metal other than palladium is present in the composition.

[0187] The molar ratio between the palladium compound and the one or more compounds of component (ii) might be in the range of from 100/1 to 1/100, more preferably 10/1 to 1/10.

[0188] Instead of comprising a mixture of the palladium compound and the compound of component (ii), the composition can be a kit-of-parts which provides the palladium compound of component (i) and the at least one compound of component (ii) and optionally the compound of component (iii) in separate containers.

[0189] The present invention also relates to a process which comprises [0190] mixing a first reactant, a second reactant and the composition of the present invention, thereby providing a reaction medium, wherein the first reactant is a compound which comprises a heterocyclic aromatic ring AR1 to which a carboxylic acid group, a carboxylate group or a carboxylic acid ester group is directly attached, and the second reactant is a compound which comprises an aromatic ring AR2 to which a halogen atom (Cl, Br or I), a pseudohalogen group (e.g. cyano, cyanate or isocyanate) or a sulfonate group (e.g. trifluoromethanesulfonate group O-Tf) is directly attached, [0191] irradiating the reaction medium by an external light source, thereby coupling the heterocyclic aromatic ring AR1 of the first reactant to the aromatic ring AR2 of the second reactant by a decarboxylative carbon-carbon cross-coupling reaction.

[0192] The product obtained by the process is a heteroaromatic biaryl compound, i.e. a compound which comprises a heterocyclic aromatic ring AR1 and an aromatic ring AR2 (which might be a carbocyclic or heterocyclic aromatic ring) being linked to each other by a carbon-carbon single bond. The heterocyclic aromatic ring AR1 originates from the first reactant, and the aromatic ring AR2 originates from the second reactant.

[0193] Preferably, the heterocyclic aromatic ring AR1 of the first reactant is 5- or 6-membered aromatic ring which contains one or more heteroatoms (e.g. up to three heteroatoms) being selected from nitrogen, oxygen and sulfur. The carboxylic acid group, carboxylate group or carboxylic acid ester group is attached to a carbon ring atom of the heterocyclic aromatic ring. Optionally, a further 5- or 6-membered aromatic ring might be fused to the heterocyclic aromatic ring, thereby forming a polycyclic aromatic ring system.

[0194] Exemplary first reactants include a substituted or unsubstituted pyridine carboxylic acid or a carboxylate or an ester thereof, a substituted or unsubstituted benzopyridine carboxylic acid or a carboxylate or an ester thereof, a pyridazine carboxylic acid or a carboxylate or an ester thereof, a benzopyridazine carboxylic acid or a carboxylate or an ester thereof, a pyrimidine carboxylic acid or a carboxylate or an ester thereof, a benzopyrimidine carboxylic acid or a carboxylate or an ester thereof, a pyrazine carboxylic acid or a carboxylate or an ester thereof, a benzopyrazine carboxylic acid or a carboxylate or an ester thereof, a pyrrole carboxylic acid or a carboxylate or an ester thereof, a benzopyrrole carboxylic acid or a carboxylate or an ester thereof, an imidazole carboxylic acid or a carboxylate or an ester thereof, a benzimidazole carboxylic acid or a carboxylate or an ester thereof, an oxazole carboxylic acid or a carboxylate or an ester thereof, a benzoxazole carboxylic acid or a carboxylate or an ester thereof, an isoxazole carboxylic acid or a carboxylate or an ester thereof, a benzisoxazole carboxylic acid or a carboxylate or an ester thereof, a thiazole carboxylic acid or a carboxylate or an ester thereof, a benzothiazole carboxylic acid or a carboxylate or an ester thereof, an isothiazole carboxylic acid or a carboxylate or an ester thereof, and a benzisothiazole carboxylic acid or a carboxylate or an ester thereof.

[0195] A carboxylic acid group is represented by the following formula: COOH

[0196] A carboxylate group is a deprotonated carboxylic acid group and is therefore represented by the following formula: COO.sup.

[0197] If a carboxylic acid ester group is attached to the heterocyclic aromatic ring of the first reactant,

[0198] it may have the following formula (XVIII):

C(O)O-A(XVIII)

[0199] wherein the residue A is derived from a N-hydroxy compound.

[0200] Accordingly, the carboxylic acid ester group might be obtained by reacting a carboxylic acid group with a N-hydroxy compound.

[0201] Exemplary N-hydroxy compounds from which residue A of the carboxylic acid ester group might be derived include oximes (ketoximes or aldoximes), N-hydroxy phthalimides, N-hydroxypyridine-2-thiones, and N-hydroxy benzotriazoles.

[0202] According to an exemplary embodiment, the residue A in Formula (XVIII) might have one of the following Formulas (XIX-1) to (XIX-6):

##STR00032## [0203] wherein in Formula (XIX-1) [0204] n is 0 or 1, [0205] m is 0 or 1, [0206] R.sup.1 and R.sup.2 are selected independently from each other from halogen (e.g. Cl or F) and halo-C.sub.1-4alkyl (e.g. CF.sub.3);

##STR00033## [0207] wherein in Formula (XIX-3) [0208] R.sup.1 is hydrogen or CF.sub.3, [0209] R.sup.2 is hydrogen or fluoro;

##STR00034## [0210] wherein in Formula (XIX-6) [0211] n is an integer from 0 to 4, [0212] R is halogen (e.g. Cl).

[0213] In Formulas (XIX-1) to (XIX-6), *- denotes the bond by which residue A is connected to the carboxylic acid ester group.

[0214] If n is 0 in Formula (XIX-1) or (XIX-6) or m is 0 in Formula (XIX-1), the aromatic ring is unsubstituted.

[0215] It might be preferred that the first reactant does not comprise a boron-carbon bond, a tin-carbon bond, a zinc-carbon bond or a magnesium-carbon bond.

[0216] The aromatic ring AR2 of the second reactant is preferably a 5- or 6-membered aromatic ring. It can be a carbocyclic ring (i.e. a ring made of carbon atoms only) or heterocyclic aromatic ring.

[0217] Optionally, it is fused to a further 5- or 6-membered aromatic ring, thereby forming a polycyclic aromatic ring system.

[0218] Attached to the aromatic ring of the second reactant is a halogen atom (e.g. Cl, Br or I), a pseudohalogen group (e.g. cyano, cyanate or isocyanate) or a sulfonate group (such as a trifluoromethanesulfonate group O-Tf).

[0219] If the aromatic ring is a heterocyclic aromatic ring, it is preferably a 5- or 6-membered aromatic ring which contains one or more (e.g. up to three) heteroatoms being selected from nitrogen, oxygen and sulfur. The halogen atom, the pseudohalogen group or the sulfonate group is attached to a carbon ring atom of the heterocyclic aromatic ring.

[0220] During the cross-coupling reaction, the carboxylic acid group, the carboxylate group or the carboxylic acid ester group is split off from the heterocyclic aromatic ring AR1; and the halogen atom, the pseudohalogen group or the sulfonate group is split off from the aromatic ring AR2; and the aromatic rings AR1 and AR2 are coupled to each other via a single bond between the carbon ring atom of AR1 to which the carboxylic acid group, the carboxylate group or the carboxylic acid ester group was attached and the carbon ring atom of AR2 to which the halogen atom, the pseudohalogen group or the sulfonate group was attached.

[0221] It might be preferred that neither the first reactant nor the second reactant comprises a boron-carbon bond, a tin-carbon bond, a zinc-carbon bond or a magnesium-carbon bond.

[0222] The reaction outlined above represents an intermolecular decarboxylative cross-coupling reaction between a first reactant and a second reactant. Typically, the first reactant and the second reactant differ from each other (i.e. they are compounds which differ in chemical structure).

[0223] Alternatively, the heterocyclic aromatic ring AR1 and the carbocyclic or heterocyclic aromatic ring AR2 might be coupled to each other by an intramolecular decarboxylative cross-coupling reaction (i.e. each of the reactant molecules containing both the heterocyclic aromatic ring AR1 and the carbocyclic or heterocyclic aromatic ring AR2).

[0224] Accordingly, the present invention also relates to a process which comprises [0225] mixing a reactant and the composition of the present invention, thereby providing a reaction medium, wherein the reactant is a compound which comprises a heterocyclic aromatic ring AR1 to which a carboxylic acid group, a carboxylate group or a carboxylic acid ester group is attached and an aromatic ring AR2 to which a halogen atom (Cl, Br or I), a pseudohalogen group (e.g. cyano, cyanate or isocyanate) or a sulfonate group (e.g. trifluoromethanesulfonate group O-Tf) is attached, [0226] irradiating the reaction medium by an external light source, thereby coupling the heterocyclic aromatic ring AR1 and the aromatic ring AR2 of the reactant to each other by a decarboxylative carbon-carbon cross-coupling reaction.

[0227] The aromatic ring AR2 can be a carbocyclic aromatic ring or a heterocyclic aromatic ring.

[0228] The preferred heterocyclic aromatic ring AR1 and (carbocyclic or heterocyclic) aromatic ring AR2 of the intramolecular coupling reaction correspond to those of the intermolecular coupling reaction. However, for the intramolecular coupling reaction, each of the reactant molecules contains both the aromatic ring AR1 and the aromatic ring AR2 linked to each other by a bivalent linker unit L.

[0229] It might be preferred that the reactant does not comprise a boron-carbon bond, a tin-carbon bond, a zinc-carbon bond or a magnesium-carbon bond.

[0230] The following statements apply to both the intermolecular and the intramolecular decarboxylative carbon-carbon cross-coupling reactions.

[0231] Typically, the reactants and the catalyst composition are mixed with each other in a solvent. The solvent may comprise a polar aprotic solvent. The solvent may comprise a high-boiling liquid having a boiling point of at least 120 C. Exemplary polar aprotic solvents include dimethylsulfoxide (DMSO), dimethylformamide (DMF), dimethylacetamide, sulfolane and ethylacetate. The reactants and the components of the catalyst composition (i.e. components (i) to (ii) and optionally component (iii)) can be added to the solvent in any order. Just as an example, each of the components of the catalyst composition might be added separately to the solvent, or the components of the catalyst composition are pre-mixed and the pre-mixture is subsequently added to the solvent.

[0232] Typically, the external light source is a source which generates artificial light.

[0233] The external light source might be a lamp such as an UV or UVVIS lamp, a LED lamp, a laser, or any combination of two or more of these external light sources.

[0234] The light emitted by the external light source may have a wavelength in the range of from 254 nm to 800 nm, preferably 360 nm to 550 nm. The light can be a monochromatic light; or may cover a continuous wavelength spectrum (e.g. in the UV and/or visible spectrum). The light reaching the reaction medium may have an irradiance of 10 to 2000 milliwatts per square centimeter. However, lower or higher irradiance values can be used as well.

[0235] Optionally, the reaction medium might be heated to a temperature of 40 C. to 90 C., more preferably 50 C. to 80 C., for assisting the decarboxylative carbon-carbon cross-coupling reaction. However, lower or higher reaction temperatures might be used as well.

[0236] It might be preferred that no compound comprising a transition metal other than palladium is present in the reaction medium.

[0237] Furthermore, the present invention relates to the use of the composition described above as a catalyst for coupling a heterocyclic aromatic ring AR1 and a carbocyclic or heterocyclic aromatic ring AR2 to each other by a light-assisted decarboxylative carbon-carbon cross-coupling reaction. As already mentioned above, the cross-coupling reaction might be an intermolecular cross-coupling or an intramolecular cross-coupling. The preferred use is for synthesis of biaryl compounds. As known to the skilled person, light assisted means that the reaction medium in which the decarboxylative cross-coupling reaction is carried out is irradiated by an external source of artificial light (e.g. a lamp such as an UV or UV/VIS lamp or a LED lamp, a laser, etc.).

EXAMPLES

Inventive Example 1 (IE1)

[0238] In Inventive Example 1 (IE1), the following reactants were used: [0239] Picolinic acid (First Reactant), i.e. a compound which comprises a heterocyclic aromatic ring AR1 to which a carboxylic acid group is attached; and [0240] 4-bromobenzotrifluoride (Second Reactant), i.e. a compound which comprises an aromatic ring AR2 to which a halogen atom is attached.

[0241] The catalyst composition added to the reaction medium contained (i) palladium acetate (i.e. a palladium compound), (ii) biphenyl (i.e. a compound of Formula (I)) and 9,10-dicyanoanthracene (i.e. a compound of Formula (II)), and (iii) BrettPhos which is a commercially available phosphine of Formula (IV-6) outlined above.

[0242] The reaction medium comprising the first reactant, the second reactant and the catalyst composition was irradiated with a LED light (400 nm).

[0243] The reactants and the desired reaction product to be obtained via decarboxylative carbon-carbon cross-coupling reaction are illustrated by the following reaction scheme:

##STR00035##

[0244] Details of the preparation procedure are as follows: [0245] To a dram vial containing a stir bar, 13.8 mg of picolinic acid, 1.2 mg of biphenyl (BP), 1.7 mg of 9,10-dicyanoanthracene (DCA), 0.84 mg of Pd(OAc).sub.2 were added. The vial was transferred to a glovebox containing a nitrogen atmosphere. In the glovebox, degassed reagents of 10.5 L of 4-bromobenzotrifluoride, 75 L of 0.05 M stock solution of BrettPhos (a phosphine of Formula IV-6)) in dioxane, and 675 L of CH.sub.3CN solvent were added to the vial. The vial was then tightly sealed and wrapped in parafilm before being taken to a purge box (nitrogen atmosphere), where 75 L of degassed aqueous 1.5 M NaOH was added. Finally, the vial was tightly capped, sealed with parafilm, and removed from the purge box. Upon exiting the purge box, an electrical tape was wrapped around the cap of the vial to ensure that oxygen contamination did not occur. The vial was then placed in the Hepatochem photoreactor setup, where temperature (at 70 C.) was controlled by a recirculating coolant (propylene glycol/water=1/1, v/v). The vial was illuminated with a 400 nm Kessil LED light (PR160L-400 nm).

[0246] After 16 hours, the reaction vial was allowed to cool to room temperature before being opened. 50 L of 3.2 M 1,3,5-trimethoxybenzene in CH.sub.3CN (internal standard for UPLC analysis) was added to the vial. For UPLC analysis, 75 L of the mixture was taken from the vial, filtered through a silica column, and washed with 1425 L of CH.sub.3CN; all solution was collected for UPLC analysis. For .sup.19F-NMR analysis, 20 L of the mixture was taken from the vial and added 600 L of CDCl.sub.3 (containing 0.1% v/v fluorobenzene as internal standard).

[0247] .sup.19F-NMR analysis confirmed that the desired decarboxylative cross-coupling reaction product 2-(4-(trifluoromethyl)phenyl)pyridine product was formed.

Comparative Example 1a (CE1a)

[0248] In Comparative Example 1a (CE1a), the same procedure as in Inventive Example 1 was repeated, except that the reaction medium was not irradiated by the external light source.

[0249] .sup.19F-NMR analysis confirmed that the desired decarboxylative cross-coupling reaction product 2-(4-(trifluoromethyl)phenyl)pyridine product was not formed.

Comparative Example 1b (CE1b)

[0250] In Comparative Example 1b (CE1b), the same procedure as in Inventive Example 1 was repeated, except that the compounds of component (ii), i.e. biphenyl and 9,10-dicyanoanthracene, were not added to the reaction medium.

[0251] .sup.19F-NMR analysis confirmed that the desired decarboxylative cross-coupling reaction product 2-(4-(trifluoromethyl)phenyl)pyridine product was not formed.

[0252] The results of Inventive Example 1 and Comparative Examples 1a and 1b are summarized in Table 1.

TABLE-US-00001 TABLE 1 Results of IE1, CE1a and CE1b Desired reaction Catalyst Irradation product Reactants Composition by LED? formed? IE1 Picolinic acid (i) Pd(OAc).sub.2 Yes Yes and (ii) DCA and BP 4-bromobenzotrifluoride (iii) a phosphine (BrettPhos) CE1a Picolinic acid (i) Pd(OAc).sub.2 No No and (ii) DCA and BP 4-bromobenzotrifluoride (iii) a phosphine (BrettPhos) CE1b Picolinic acid (i) Pd(OAc).sub.2 Yes No and (iii) a phosphine 4-bromobenzotrifluoride (BrettPhos) DCA: 9,10-Dicyanoanthracene BP: Biphenyl

Inventive Example 2 (IE2)

[0253] In Inventive Example 2 (IE2), the following reactants were used: [0254] Picolinic acid ester (First Reactant), i.e. a compound which comprises a heterocyclic aromatic ring (AR1) to which a carboxylic acid ester group is attached; and [0255] 4-bromobenzotrifluoride (Second Reactant), i.e. a compound which comprises an aromatic ring (AR2) to which a halogen atom is attached.

[0256] The picolinic acid ester had the following chemical formula:

##STR00036##

[0257] The catalyst composition added to the reaction medium contained (i) palladium acetylacetonate (i.e. a palladium compound), (ii) an iridium complex of formula (III-4) outlined above, and (iii) tBuXPhos which is a commercially available phosphine of Formula (IV-4) outlined above.

[0258] The reaction medium was irradiated with a blue light emitting diode.

[0259] The reactants and the desired reaction product to be obtained via decarboxylative carbon-carbon cross-coupling are illustrated by the following reaction scheme:

##STR00037##

[0260] Details of the preparation process are as follows:

[0261] To a dram vial containing a stir bar, 150 L of 0.005 M stock solution of the iridium complex of Formula (III-4) in CH.sub.3CN was introduced; the solvent was then evaporated in a vacuum oven leaving behind the iridium complex. 38.1 mg of the picolinic acid ester and 1.1 mg of Pd(acac).sub.2 were then added to the vial. The vial was transferred to a glovebox containing a nitrogen atmosphere. In the glovebox, degassed reagents of 10.5 L of 4-bromobenzotrifluoride, 75 L of 0.05 M stock solution of t-BuXPhos (a phosphine of Formula (IV-4)) in dioxane, and 675 L of DMSO solvent were added to the vial. The vial was tightly capped, sealed with parafilm, and removed from the glovebox. Upon exiting the glovebox, an electrical tape was wrapped around the cap of the vial to ensure that oxygen contamination did not occur. The vial was then placed in the Hepatochem photoreactor setup, where temperature (at 70 C.) was controlled by a recirculating coolant (propylene glycol/water=1/1, v/v). The vial was illuminated with a Kessil Tuna Blue LED light (A160WE).

[0262] After 16 hours, the reaction vial was allowed to cool to room temperature before being opened. 50 L of 1.6 M biphenyl in DMSO (internal standard for HPLC analysis) was added to the vial. For HPLC analysis, 75 L of the mixture was taken from the vial, filtered through a silica column, and washed with 1425 L of CH.sub.3CN; all solution was collected for HPLC analysis. For .sup.19F-NMR analysis, 20 L of the mixture was taken from the vial and added 600 L of CDCl.sub.3 (containing 0.1% v/v fluorobenzene as internal standard).

[0263] .sup.19F-NMR analysis confirmed that the desired decarboxylative cross-coupling reaction product 2-(4-(trifluoromethyl)phenyl)pyridine product was formed.

Comparative Example 2a (CE1a)

[0264] In Comparative Example 2a (CE2a), the same procedure as in Inventive Example 2 was applied, except that the reaction medium was not irradiated by the LED.

[0265] .sup.19F-NMR analysis confirmed that the desired decarboxylative cross-coupling reaction product 2-(4-(trifluoromethyl)phenyl)pyridine product was not formed.

Comparative Example 2b (CE2b)

[0266] In Comparative Example 2b (CE2b), the same procedure as in Inventive Example 2 was applied, except that the compound of component (ii), i.e. the iridium complex, was not added to the reaction medium.

[0267] .sup.19F-NMR analysis confirmed that the desired decarboxylative cross-coupling reaction product 2-(4-(trifluoromethyl)phenyl)pyridine product was not formed.

[0268] The results of Inventive Example 2 and Comparative Examples 2a and 2b are summarized in Table 2.

TABLE-US-00002 TABLE 2 Results of IE2, CE2a and CE2b Desired reaction Catalyst Irradation product Reactants Composition by LED? formed? IE2 Picolinic acid ester (i) Pd(acac).sub.2 Yes Yes and (ii) Ir complex of 4-bromobenzotrifluoride Formula (III-4) (iii) a phosphine (tBuXPhos) CE2a Picolinic acid ester (i) Pd(acac).sub.2 No No and (ii) Ir complex of 4-bromobenzotrifluoride Formula (III-4) (iii) a phosphine (tBuXPhos) CE2b Picolinic acid ester (i) Pd(acac).sub.2 Yes No and (iii) a phosphine 4-bromobenzotrifluoride (tBuXPhos)

[0269] From the Inventive Examples 1 and 2 and the Comparative Examples 1a, 1b, 2a and 2b, the following can be concluded:

[0270] If a heteroaryl carboxylic acid or a carboxylate or an ester thereof is reacted with a (hetero)aryl halide (or a (hetero)aryl pseudohalide or a (hetero)aryl sulfonate) in a reaction medium [0271] to which the catalyst composition of the present invention has been added and [0272] which is irradiated by an external light source,

[0273] a heteroaromatic biaryl compound can be formed by a decarboxylative carbon-carbon cross-coupling reaction even at rather moderate reaction temperature (e.g. 70 C.).

[0274] However, no heteroaromatic biaryl compound is formed from these reactants at moderate reaction temperature if [0275] the reaction medium comprises the palladium compound and is irradiated by an external light source but no compound of component (ii) is present, or [0276] the reaction medium comprises both the palladium compound and at least one compound of component (ii) but is not irradiated by an external light source.

[0277] While the invention has been described in detail and with reference to specific embodiments thereof, it will be apparent to one skilled in the art that various changes and modifications can be made therein without departing from the spirit and scope thereof. Thus, it is intended that the invention covers the modifications and variations of this invention provided they come within the scope of the appended claims and their equivalents.